#USA #New York #AI Solutions #Clinical Trials #PhaseV

PhaseV Showcases Innovative AI in Clinical Development

PhaseV, a frontrunner in AI and machine learning (ML) for clinical development, is gearing up to participate in several key biotech and data science conferences in the coming weeks. The company is poised to highlight its advancements in utilizing AI for optimizing clinical trials. This includes the integration of sophisticated analytics, biostatistics, and structured trial designs aimed at enhancing efficiency, ensuring regulatory compliance, and speeding up the introduction of new treatments for various diseases such as oncology and inflammatory bowel conditions.

Upcoming Events and Presentations

The first major event on the schedule is the IBD Innovate 2025, taking place from April 9-10 in New York, NY, where PhaseV will exhibit its innovative solutions in the exhibition hall.

Next, PhaseV will be part of the Duke Industry Statistics Symposium 2025 from April 9-11 in Durham, NC. During this symposium, Raviv Pryluk, PhD, the CEO and Co-founder of PhaseV, will moderate a panel session titled Recent Advances in Computing, Optimization, and Causal Inference for Adaptive Clinical Trials. He will also present on Causal Machine Learning for Estimating Uncertainty and Detecting Subgroups in Adaptive Clinical Trials, showcasing the transformative potential of AI-driven methodologies in clinical research.

Further, attendees can look forward to the Joint Statistical Meetings (JSM) 2025 happening from August 2-7 in Nashville, TN. Here, both Raviv Pryluk and Senior Director of Data Science and Statistics Brad Carlin will present critical findings on adaptive clinical trials, along with new statistical methods for robust analysis from small sample sizes.

In addition, PhaseV's Senior Data Scientist, Tzviel Frostig, will share insights at the 13th International Conference on Multiple Comparison Procedures (MCP 2025) from August 12-15 in Philadelphia, PA, detailing methods for identifying treatment responders in clinical trials.

Expert Insights

Raviv Pryluk emphasizes the necessity of integrating AI with advanced statistical modeling amidst the increasing complexity of clinical development. He states, "As the healthcare landscape evolves, optimizing efficiency and delivering accurate results is paramount, and our commitment to scientific rigor puts us at the forefront of transforming clinical trial design and execution."

PhaseV’s impressive portfolio includes partnerships with over 30 global pharmaceutical and biotech companies that leverage its advanced technology to enhance clinical development processes. The platform enables biopharma sponsors and CROs to design and carry out adaptive, Bayesian, and fixed clinical trials effectively. This technology has reportedly reduced trial costs by up to 25% and shortened enrollment duration and trial periods by as much as 40%, while also increasing the chances of successful trials by approximately 30%.

The Future of AI in Clinical Development

The methodologies developed by PhaseV have the potential not just to streamline processes but also to fundamentally change how clinical trials are designed and executed. By applying rigorous statistical techniques and real-world evidence, PhaseV is reshaping the landscape of clinical research. More than ever, the need for innovative solutions in drug development aligns perfectly with PhaseV’s mission to optimize patient outcomes through advanced analytics.

As PhaseV continues to push the boundaries of what's possible, the upcoming events are set to be a pivotal moment in demonstrating the transformative impact of AI on the future of clinical development.

For further insights into PhaseV’s cutting-edge solutions, visit www.PhaseVTrials.com and connect with them on LinkedIn.